World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
93
Citations
31301
World Ranking
971
National Ranking
29

Medicine

D-Index
93
Citations
31301
World Ranking
10902
National Ranking
394

Licia Rivoltini publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Licia Rivoltini sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 322 publications — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Licia Rivoltini D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Licia Rivoltini sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 93 D-Index — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Licia Rivoltini is affiliated with Fondazione IRCCS Istituto Nazionale dei Tumori in Italy. Their research spans multiple areas within medicine, with a significant focus on oncology and related biomedical sciences. Rivoltini's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology, supported by a substantial body of published work.

Their expertise is concentrated in several subfields of study, including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Immunology
  • Molecular Biology
  • Cancer Research

Rivoltini's research topics frequently cover key areas related to cancer and the immune system, such as:

  • Cancer Immunotherapy and Biomarkers
  • Immune cells in cancer
  • Immunotherapy and Immune Responses
  • Ferroptosis and cancer prognosis
  • Melanoma and MAPK Pathways
  • Extracellular vesicles in disease
  • MicroRNA in disease regulation

Their scholarly contributions have appeared in numerous scientific venues, with repeated publications in:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancers
  • Frontiers in Immunology

Some recent publications by Rivoltini or close collaborators include:

  • Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility, 2020, Nature Genetics
  • Extracellular vesicles in anti-tumor immunity, 2021, Seminars in Cancer Biology
  • Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol, 2021, BMJ Open
  • Fasting-mimicking diet plus chemotherapy in breast cancer treatment, 2020, Nature Communications
  • Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?, 2020, Journal of Clinical Medicine

Frequently collaborating researchers include:

  • Veronica Huber
  • Viviana Vallacchi
  • Luca Lalli
  • Monica Rodolfo
  • Filippo de Braud

Best Publications

  • Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

    Yutaka Kawakami;Siona Eliyahu;Cynthia H. Delgado;Paul F. Robbins

  • Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

    Yutaka Kawakami;Siona Eliyahu;Kazuyasu Sakaguchi;Paul F. Robbins

  • High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

    Mariantonia Logozzi;Angelo De Milito;Luana Lugini;Martina Borghi

  • Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

    Paola Filipazzi;Roberta Valenti;Veronica Huber;Lorenzo Pilla

  • Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

    Giovanna Andreola;Licia Rivoltini;Chiara Castelli;Veronica Huber

  • Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation

    Veronica Huber;Chiara Camisaschi;Angela Berzi;Simona Ferro

  • Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

    Arianna Calcinotto;Paola Filipazzi;Matteo Grioni;Manuela Iero

  • Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.

    Francesca Romana Ponziani;Sherrie Bhoori;Chiara Castelli;Lorenza Putignani

  • Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-β–Mediated Suppressive Activity on T Lymphocytes

    Roberta Valenti;Veronica Huber;Paola Filipazzi;Lorenzo Pilla

  • Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

    Veronica Huber;Stefano Fais;Manuela Iero;Luana Lugini

  • Tumour-released exosomes and their implications in cancer immunity

    M Iero;R Valenti;V Huber;P Filipazzi

  • Tumor-Released Microvesicles as Vehicles of Immunosuppression

    Roberta Valenti;Veronica Huber;Manuela Iero;Paola Filipazzi

  • Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy

    Valentina Ciravolo;Veronica Huber;Gaia C. Ghedini;Elisabetta Venturelli

  • Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

    Giorgio Parmiani;Chiara Castelli;Piero Dalerba;Roberta Mortarini

  • Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

    Filiberto Belli;Alessandro Testori;Licia Rivoltini;Michele Maio

  • Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs

    Francesca Luciani;Massimo Spada;Angelo De Milito;Agnese Molinari

  • Immune Surveillance Properties of Human NK Cell-Derived Exosomes

    Luana Lugini;Serena Cecchetti;Veronica Huber;Francesca Luciani

  • Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

    Licia Rivoltini;Yutaka Kawakami;Kazuyasu Sakaguchi;Scott Southwood

  • Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

    Giorgio Parmiani;C. Castelli;L. Pilla;M. Santinami

  • Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

    Giuseppe Lo Russo;Massimo Moro;Michele Sommariva;Valeria Cancila

  • Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

    Janice Nicole Cormier;Michael L. Salgaller;Tracy Prevette;Kathleen C. Barracchini

Frequent Co-Authors

Giorgio Parmiani
Giorgio Parmiani University of Siena
Chiara Castelli
Chiara Castelli University of Milan
Michele Maio
Michele Maio University of Siena
Antonello Villa
Antonello Villa University of Milano-Bicocca
Stefano Fais
Stefano Fais Istituto Superiore di Sanità
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health
Filippo de Braud
Filippo de Braud University of Milan
Mario P. Colombo
Mario P. Colombo Fondazione IRCCS Istituto Nazionale dei Tumori
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Yutaka Kawakami
Yutaka Kawakami International University Of Health And Welfare Atami Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can expand career opportunities significantly. Many professionals find that pursuing nursing degrees online offers a practical pathway to roles that complement immunological expertise. For instance, students looking to transition into nursing can consider online RN programs for non nurses in Florida, which provide flexible options for newcomers entering the nursing field.

Accelerated programs are also popular for those aiming to fast-track their nursing credentials. Programs recognized as the easiest accelerated nursing programs to get into offer a streamlined learning experience, ideal for students balancing other commitments or seeking quick entry into the workforce.

Additionally, for those interested in foundational nursing roles, easy LPN programs to get into can be a great starting point. Licensed Practical Nurses often support immunology-related clinical work, rounding out teams focused on patient care and treatment.

To further advance clinical practice and specialization, easiest NP programs to get into provide a pathway for RNs to become Nurse Practitioners. This role often involves more direct patient management and can intersect closely with immunology in areas such as infectious diseases and immunotherapy.

Best Scientists Citing Licia Rivoltini

Trending Scientists

Recently Published Articles